Shohdy, Kyrillus SAlmeldin, Doaa SFekry, Madonna AIsmail, Mahmoud AAboElmaaref, Nedal AElSadany, Esraa GHamza, Baher MEl‑Shorbagy, Fatma HAli, Ahmad SAttia, HanaaKassem, Loay2021-12-192021-12-192021-12https://doi.org/10.1186/s43046-021-00096-yhttp://repository.msa.edu.eg/xmlui/handle/123456789/4801Background: Pathological complete response (pCR) is a surrogate for the efcacy of neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (LABC). We analyzed the predictive clinical factors for pathological responses and survival outcomes in a cohort of Egyptian patients. Methods: We evaluated the medical records of patients with breast cancer who received NCT in our academic insti‑ tute. Survival curves were estimated with the Kaplan-Meier method. Cox proportional models were used for multiple regression analysis. Results: Our cohort included 368 patients with a median age of 48 years (range 21–70). The median follow-up time was 3 years. The clinical tumor stage (T3–4) represented 58%, with 80% having positive axillary nodes. The luminal subgroup prevailed by 68%. The objective response rate (ORR) reached 78%, and 16% of patients achieved pCR. The clinical node stage and optimal chemotherapy were associated with higher ORR (p = 0.035 and p = 0.001, respec‑ tively). Predictors of pCR were clinical T-stage (p = 0.026), high Ki-67 index > 20 (p = 0.05), and receiving optimal chemotherapy (p = 0.014). The estimated 3-year disease free-survival (DFS) was 53%. Receptor status, achieving ORR, and pCR were associated with better DFS with hazard ratios of 0.56, p = 0.008; 0.38, p = 0.04; and 0.28, p = 0.007, respectively. Conclusions: Luminal tumors still draw beneft from neoadjuvant chemotherapy in terms of clinical response and breast conservative surgery. Treatment escalation to those who did not achieve pCR requires more investigation, given a higher recurrence rate in real-world experience.en-USBreast cancerPathological complete responseSurvival outcomesArticlehttps://doi.org/10.1186/s43046-021-00096-y